Results from a preclinical study in mice and a collaborative clinical study in patients show that the type 2 immune response -- associated with parasitic infection and thought to play a negative role ...

Stimulating a key metabolic pathway in T cells can make them work more effectively against tumors when combined with immune ...

Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.

OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update Financial and business highlights Total H1 2024 incomes of €82.5 million thanks to Company's new partnerships.Ne ...

Hudson Therapeutics, a leading innovator in therapeutic solutions and a US subsidiary of Shaperon, announced Shaperon’s entry ...

Dr. Jeremy Farrar, WHO’s Chief Scientist, emphasized the importance of strengthening country-led R&D and integrating clinical ...

Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical powering of the study expected to be superior to 95% for ...

Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in ...

Eradivir $10.25M Series A funding round Two Eradivir employees conduct research on the company’s EV25 influenza therapeutic.

Scientists have uncovered critical differences between how innate-like T cells mature in humans and mice. Early in life, most innate-like T cells in the human thymus aren't able to use all of their ...

Surrozen is pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration. The milestone achievement triggers a $10 million payment to Surrozen as part ...

Two new therapies have successfully cleared tau aggregates in preclinical and mouse models, showing potential as dementia ...